Publicação
Synergy valuation in the Pfizer - seagen acquisition - influencing factors on acquisition premiums in R & D intensive industries for Us acquirers
| Resumo: | This thesis examines the Pfizer-Seagen acquisition, a pivotal deal in the pharmaceutical industry. It starts with a literature review on valuation methods and further analyses the strategic motivations and financial implications of mergers and acquisitions in the industry. The thesis assesses both companies' market positions, strategies, and financial health, to perform two comprehensive standalone valuations. It also conducts a combined valuation to explore potential synergies and economically feasible offer prices, comparing these to Pfizer's announced offer. Additionally, the thesis analyses the factors influencing premiums in M&As and stock reactions post-announcement in R&D intensive industries. |
|---|---|
| Autores principais: | Wehringer, Mark |
| Assunto: | Merger and acquisitions Valuation Pharmaceutical industry Pfizer Seagen |
| Ano: | 2024 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| Resumo: | This thesis examines the Pfizer-Seagen acquisition, a pivotal deal in the pharmaceutical industry. It starts with a literature review on valuation methods and further analyses the strategic motivations and financial implications of mergers and acquisitions in the industry. The thesis assesses both companies' market positions, strategies, and financial health, to perform two comprehensive standalone valuations. It also conducts a combined valuation to explore potential synergies and economically feasible offer prices, comparing these to Pfizer's announced offer. Additionally, the thesis analyses the factors influencing premiums in M&As and stock reactions post-announcement in R&D intensive industries. |
|---|